Perioperative antiviral therapy for chronic hepatitis B-related hepatocellular carcinoma

Hangzhou, China

Perioperative antiviral therapy for chronic hepatitis B-related hepatocellular carcinoma

Qiang Wei, Xiao Xu, Qi Ling, Bo Zhou and Shu-Sen Zheng

Hangzhou, China

BACKGROUND:After effective treatment with antiviral agent, patients with low serum hepatitis B virus (HBV) DNA level had a low incidence of hepatocellular carcinoma (HCC). HBV reactivation after HCC surgery is associated with HCC recurrence. To date, there are no universal guidelines for the perioperative antiviral treatment of patients with chronic hepatitis B, let alone antiviral therapy in patients with HBV-related HCC. The present analysis is trying to develop a perioperative anti-HBV treatment protocol.

DATA SOURCES:A literature search of PubMed was performed, the key words were "perioperative" "antiviral therapy", "hepatocellular carcinoma" and "chronic hepatitis B". All of the information was collected.

RESULTS:Relevant documents showed that reactivation of HBV replication played a direct role in the late recurrence of HCC after surgical resection. The well control of viral load before and after operation signif i cantly increased tumor-free survival. Many drugs are used in antiviral therapy including interferon alpha and nucleoside analogues. Foscarnet, twoagent or even multiagent of nucleoside analogues is necessary for perioperative antiviral treatment of patients with chronic hepatitis B related HCC.

CONCLUSIONS:HBV reactivation after HCC surgery induces hepatitis fl are and hepatocarcinogenesis, thus lifelong and vigorous control of HBV is very important in patients with chronic hepatitis B and HBV-related HCC. A uniform guideline is necessary to rapidly reduce HBV DNA to a lower level in perioperation.

(Hepatobiliary Pancreat Dis Int 2013;12:251-255)

hepatitis B virus; hepatocellular carcinoma; antiviral therapy

Introduction

Hepatocellular carcinoma (HCC), a highly prevalent and lethal cancer, is the third leading cause of cancer-related death worldwide.[1]HBV infection is a risk factor for HCC and HBV-related HCC is a leading cause of cancer death in China.[2]As a curative treatment, partial hepatectomy provides potentially curative outcome for HCC patients who are indicated for this procedure.[3-5]However, the tumor recurrence rate after surgery remains high, with a 5-year recurrence rate of more than 70% in most studies.[6-9]Recently, accumulating evidence has shown that for patients with HBV infection, a high serum HBV DNA level either before or after operation is associated with higher risk of HCC recurrence.[10-17]In addition, hepatectomy could reactivate HBV replication, especially in patients who did not receive any antiviral therapy.[11]Reactivation of HBV replication occurred in 28% patients after liver resection for HCC.[18]A previous study[19]showed that antiviral therapy after hepatectomy conferred a survival benef i t in patients with HBV-related HCC. Thus, to prevent postoperative HCC recurrence, effective antiviral therapy should be initiated in patients with a high preoperative serum HBV DNA level.

A recent meta-analysis found that antiviral therapy with nucleotide analogues decreased HCC-related mortality and HCC recurrence after surgery, and improved overall survival in patients with hepatitis B related HCC.[20]However, for patients undergoing surgical treatment for HBV-related HCC, most of the studies focused on the antiviral therapy after resection, whereas studies focused on the antiviral therapy before resection are rare. Preoperative antiviral therapy is recommended for HBV carriers who are going to receive partial hepatectomy. In addition, there is nouniversally accepted protocol to eradicate/decrease viral load perioperatively for patients with HBV-related HCC undergoing partial hepatectomy.

Therapeutic scheme

Perioperative high HBV DNA level is related to postoperative HCC recurrence, thus, effective suppression of serum HBV DNA level is a marker of eff i cacy for antiviral therapy.[21]Because operative treatment should be performed soon after the diagnosis of resectable HCC. Perioperative anti-HBV therapy not only rapidly reduces HBV DNA level in a short period of time, but also effectively prevents HBV DNA rebound after operation. The following is some therapeutic schemes used currently.

Interferon alpha (IFN-α)

The fi rst agent for a successful treatment of chronic hepatitis B (CHB) was IFN-α. IFN-α has both antiviral and antiproliferative properties. Some meta-analyses have shown that IFN-α has a benef i cial effect on HBeAg eradication and sustained reduction in serum HBV DNA level.[22,23]

Although one review of more than one thousand CHB patients found that IFN-α had no or minimal overall effect in preventing HCC, some interferonresponders indeed had a benef i cial outcome.[24]This study indicated that it is the direct anti-HBV effect of IFN-α that plays an important role in preventing HCC recurrence, not its immune modulation and antitumorgenesis. In addition, a recent published metaanalysis of 1180 HBV/HCV patients, enrolled in nine randomized trials and four cohort studies, showed that conventional IFN-α improved the 1-, 2-, and 3-year recurrence-free survival by 7.8%, 35.4% and 14.0%, respectively.[25]These studies provided promising effects of IFN-α in preventing HCC recurrence and prolonging survival, while the effect of interferon therapy in preventing HBV-related HCC recurrence was controversial.[26,27]To investigate the effect of adjuvant IFNα-2b on the recurrence-free survival of patients with postoperative viral hepatitis-related HCC, Chen et al[28]conducted a randomized, observation-controlled and phase III trial showing that adjuvant IFNα-2b only temporarily suppressed viral replication during the period of treatment but it was not effective in reducing the postoperative recurrence of HCC.

Besides, the sustained antiviral response is only 30%-40%. IFN-α is associated with numerous adverse effects, some of which can be severe.[23]In patients with advanced liver disease, IFN-α therapy may have a signif i cant risk of hepatic decompensation with lifethreatening complications including icterus, hepatic encephalopathy, ascites, variceal bleeding or death.[29]

Long-term follow-up showed that a majority of patients still have detectable HBV DNA after interferon treatment.[30,31]In addition, most studies[32,33]failed to demonstrate a reduced incidence of HCC.

Monotherapy of nucleoside analogues (NAs)

Currently fi ve NAs are approved in the treatment of CHB. They are lamivudine, adefovir dipivoxil (ADV), telbivudine, entecavir and tenofovir disoproxil fumarate (TDF). These agents can be used against HBV, HCV, herpes simplex, and HIV. During the last decade, the rise of oral NAs has changed the treatment landscape for HBV infections. It is conf i rmed that NAs slow the progression from severe liver disease to cirrhosis as well as to HCC.[34]

The fi rst agent of NAs is lamivudine which is an oral NA that inhibits DNA synthesis by terminating the nascent proviral DNA chain. It rapidly reduces both serum HBV DNA level and transaminase concentrations.[35]Lamivudine is the primary antiviral agent in the majority of patients, and it is well known that lamivudine not only delays the disease progression but also reduces the incidence of HCC. A research showed that HCC occurred in 3.9% of the patients treated with lamivudine; the incidence rate of HCC was 7.4% in the placebo group.[36]These results indicated that anti-HBV nucleoside therapy may be a useful approach to reduce the recurrence of HCC in patients with HBV-related HCC after surgery. A recent study[37]on patients treated with lamivudine (100 mg/d) showed that lamivudine may be effective in improving disease-free survival after resection of HBV-related HCC in patients with a high viral load. Chan and colleagues[19]recommended that lamivudine was the fi rst choice in antiviral therapy after hepatectomy. However, Chan and coworkers also demonstrated the high potency of entecavir against HBV DNA activity. A more recent study on patients with advanced HBV-related HCC revealed that single use of lamivudine could neither reduce the shortterm recurrence of HCC nor improve the disease-free survival.[38]

TDF was initially approved for the treatment of HIV infection and then for treatment of CHB in 2008. Given the potent antiviral eff i cacy, low resistance rate and minimal toxicity, TDF can achieve a long-term effective HBV DNA suppression and has the potential to become one of the "ideal" treatment options for CHB.[39]However, there were no validated data so far for the application of TDF on the perioperative antiviral treatment.

Multiple therapies of NAs

The major problem with long-term monotherapy of NAs is drug resistance. The incidence rate of lamivudine resistance was about 14%-39%.[37,38,40]The cumulative rate of genotypic resistance to ADV in 5 years was 20%-29%.[41,42]The rate of resistance to telbivudine was 25.1% in HBeAg-positive patients and 10.8% in HBeAgnegative patients in 2 years.[43]A study[44]showed a very low rate (1.2%) of viral resistance to entecavir in a longterm treatment of CHB.

From the studies above we summarized that a monotherapy of NAs should be avoided in most cases. If initial monotherapy fails, a second drug with a nonoverlapping resistance prof i le should be added.[45]In a study,[38]lamivudine was used at an oral dose of 100 mg per day, starting within the fi rst postoperative week. When YMDD mutation was conf i rmed, ADV tablets at a dose of 10 mg per day was added. As a result, the overall survival was improved for those patients with postoperative antiviral therapy.

Due to drug resistance, application of two-agent or even multiagent of NAs is necessary. In many centers, lamivudine-based antiviral therapy was recently applied to patients after hepatic resection for HBV-related HCC and it was found to improve liver function, decrease the risk of liver failure and HCC recurrence.[17,37,46]The addition of adefovir to ongoing lamivudine therapy could achieve the excellent virological and biochemical response in lamivudine-resistant patients. However, these combinations had no effect on the suppression of hepatocarcinogenesis.[47]Jayakumar et al[48]found that entecavir plus tenofovir was more effective in reducing the HBV DNA level than lamivudine plus adefovir. However, combined lamivudine and adefovir was not too inferior, especially when cost of treatment was taken into consideration.

Others

Foscarnet (PFA), a viral DNA polymerase inhibitor, is initially used in the treatment of herpes viral infection. It is a structural mimic of the anion pyrophosphate that selectively inhibits the pyrophosphate binding site on viral DNA polymerases at concentrations that do not affect human DNA polymerases.[49]PFA is administered by intravenous infusion with the advantage that it can be applied to fasting patients who can not use the antiviral drugs administered orally. In addition, the effect of intravenous infusion is more reliable than that of oral administration. So PFA fi ts the requirement of rapidly reducing HBV DNA level in a short term. PFA has been used in the patients with hepatitis B. Han and colleagues[50]found that PFA inhibited HBV DNA replication in HBV-transfected human HepG2 cells and reduced serum HBeAg and HBV DNA copies in patients. However, a large, random and controlled clinical trial is needed to evaluate the antiviral effect of PFA.

A phase II clinical trial has been performed in the First Aff i liated Hospital, Zhejiang University School of Medicine (Title: Perioperative hepatitis B virus load control strategies and molecular mechanisms of antirecurrence and metastasis in hepatic cancer. Registration number: ChiCTR-TRC-11001683). The adult patients with untreated HCC, HBsAg positive and HBV DNA≥104/mL were enrolled in this trial. According to the perioperative antiviral therapy, the patients were randomly divided into lamivudine, lamivudine+PFA, lamivudine+ADV and entecavir groups. The perioperative anti-HBV effect will be observed and compared. This is the fi rst research in the world that focused on fi nding appropriate perioperative antiviral treatment of HBV-related HCC. This trial will be helpful in establishing a protocol to reduce postoperative HBV and HCC recurrence.

Antiviral treatment duration

Future perspectives

The well control of viral load before and after operation improves tumor-free survival. Most of the studies are related to antiviral therapy after resection, but very fewfocus on the antiviral therapy for HCC before resection. In addition, although current analysis suggests that HBV reactivation after HCC surgery induce hepatitis fl are and hepatocarcinogenesis, there are no universally accepted guidelines of perioperative antiviral therapy for the patients with HBV-related HCC. A prospective, randomized and controlled clinical trial is necessary to establish a treatment guideline for these patients.

Contributors:WQ and XX proposed the study and wrote the fi rst draft. All authors contributed to the design and interpretation of the study and to further drafts. ZSS is the guarantors.

Funding:This work was supported by grants from the National High Technology Research and Development Program of China (863 Program 2012AA020204), the Program of Zhejiang Medical and Health Platform (2011ZDA007) and Program for New Century Excellent Talents in University (NCET).

Ethical approval:Not needed.

Competing interest:No benef i ts in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

1 Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917.

这个畜生。牛皮糖转身拿起那个蛇皮袋出了门。刚走几步，听见村长在后面喊，我陪你去。一路上村长不断解释说，不要急，没什么大事，说说清楚就行了。

2 Liu J, Fan D. Hepatitis B in China. Lancet 2007;369:1582-1583.

3 Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999;229:322-330.

4 Ng KK, Vauthey JN, Pawlik TM, Lauwers GY, Regimbeau JM, Belghiti J, et al. Is hepatic resection for large or multinodular hepatocellular carcinoma justif i ed? Results from a multiinstitutional database. Ann Surg Oncol 2005;12:364-373.

5 Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.

6 Poon RT, Fan ST, Lo CM, Liu CL, Ng IO, Wong J. Longterm prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol 2000;18:1094-1101.

7 Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002;235:373-382.

8 Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fi xed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359:1995-2004.

9 Wong GL, Wong VW, Tan GM, Ip KI, Lai WK, Li YW, et al. Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int 2008;28:79-87.

10 Kubo S, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T, Yamamoto T, et al. Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma. Cancer 2000;88:1016-1024.

11 Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.

12 Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol 2008;103:1663-1673.

13 Kim BK, Park JY, Kim do Y, Kim JK, Kim KS, Choi JS, et al. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int 2008;28:393-401.

14 Sherman M. Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment. Cleve Clin J Med 2009;76: S6-9.

15 Wu JC, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009;51:890-897.

16 Huang L, Li J, Lau WY, Yan J, Zhou F, Liu C, et al. Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma. J Gastroenterol Hepatol 2012;27:158-164.

17 Yang T, Lu JH, Zhai J, Lin C, Yang GS, Zhao RH, et al. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. Eur J Surg Oncol 2012;38:683-691.

18 Kubo S, Nishiguchi S, Hamba H, Hirohashi K, Tanaka H, Shuto T, et al. Reactivation of viral replication after liver resection in patients infected with hepatitis B virus. Ann Surg 2001;233:139-145.

19 Chan AC, Chok KS, Yuen WK, Chan SC, Poon RT, Lo CM, et al. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg 2011;146:675-681.

20 Wong JS, Wong GL, Tsoi KK, Wong VW, Cheung SY, Chong CN, et al. Meta-analysis: the eff i cacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2011;33:1104-1112.

21 Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of eff i cacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003;37:1309-1319.

22 Tinè F, Liberati A, Craxì A, Almasio P, Pagliaro L. Interferon treatment in patients with chronic hepatitis B: a metaanalysis of the published literature. J Hepatol 1993;18:154-162.

23 Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-323.

24 Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2004;127:S303-309.

25 Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol 2010;52:889-894.

26 Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Müllhaupt B, Clavien PA. Systematic review and metaanalysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009;96: 975-981.

27 Lau WY, Lai EC, Lau SH. The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int 2009;8:124-133.

28 Chen LT, Chen MF, Li LA, Lee PH, Jeng LB, Lin DY, et al. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg 2012;255:8-17.

29 Nevens F, Goubau P, Van Eyken P, Desmyter J, Desmet V, Fevery J. Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon alpha. Liver 1993;13:15-19.

30 Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009;136:2169-2179. e1-4.

31 Wong VW, Wong GL, Yan KK, Chim AM, Chan HY, Tse CH, et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:1945-1953.

32 Truong BX, Seo Y, Kato M, Hamano K, Ninomiya T, Katayama M, et al. Long-term follow-up of Japanese patients with chronic hepatitis B treated with interferon-alpha. Int J Mol Med 2005;16:279-284.

33 Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007;46:45-52.

34 Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during longterm lamivudine therapy. Gastroenterology 2003;124:105-117.

35 Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-68.

36 Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531.

37 Kubo S, Tanaka H, Takemura S, Yamamoto S, Hai S, Ichikawa T, et al. Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol Res 2007;37:94-100.

38 Li N, Lai EC, Shi J, Guo WX, Xue J, Huang B, et al. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol 2010;17:179-185.

39 Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011;53:763-773.

40 Koda M, Nagahara T, Matono T, Sugihara T, Mandai M, Ueki M, et al. Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function. Intern Med 2009;48:11-17.

41 Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-1751.

42 Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, et al. Long-term eff i cacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008;48:750-758.

43 Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136: 486-495.

44 Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514.

45 Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009;137:1593-608. e1-2.

46 Chuma M, Hige S, Kamiyama T, Meguro T, Nagasaka A, Nakanishi K, et al. The inf l uence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol 2009;44:991-999.

47 Elefsiniotis I, Buti M, Jardi R, Vezali E, Esteban R. Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance. Eur J Intern Med 2009;20:478-481.

48 Jayakumar R, Joshi YK, Singh S. Laboratory evaluation of three regimens of treatment of chronic hepatitis B: tenofovir, entecavir and combination of lamivudine and adefovir. J Lab Physicians 2012;4:10-16.

49 Meyer PR, Rutvisuttinunt W, Matsuura SE, So AG, Scott WA. Stable complexes formed by HIV-1 reverse transcriptase at distinct positions on the primer-template controlled by binding deoxynucleoside triphosphates or foscarnet. J Mol Biol 2007;369:41-54.

50 Han YX, Xue R, Zhao W, Zhou ZX, Li JN, Chen HS, et al. Antiviral therapeutic eff i cacy of foscarnet in hepatitis B virus infection. Antiviral Res 2005;68:147-153.

51 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacif i c consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263-283.

52 Wong DK, Huang FY, Lai CL, Poon RT, Seto WK, Fung J, et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 2011;54:829-836.

Received October 19, 2012

Accepted after revision April 25, 2013

AuthorAff i liations:Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Aff i liated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China (Wei Q, Xu X, Ling Q, Zhou B and Zheng SS)

Shu-Sen Zheng, MD, PhD, FACS, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Aff i liated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China (Tel/Fax: 86-571-87236567; Email: zyzss@zju. edu.cn)

© 2013, Hepatobiliary Pancreat Dis Int. All rights reserved.

10.1016/S1499-3872(13)60041-7